Details
| Titel in Übersetzung | Decision support through economic evaluation from the perspective of science in Germany |
|---|---|
| Originalsprache | Deutsch |
| Seiten (von - bis) | 660-667 |
| Seitenumfang | 8 |
| Fachzeitschrift | Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz |
| Jahrgang | 55 |
| Ausgabenummer | 5 |
| Frühes Online-Datum | 21 Apr. 2012 |
| Publikationsstatus | Veröffentlicht - Mai 2012 |
Abstract
For decades, economic evaluation studies, or cost-benefit analyses (CBA), have been a tool for decision support in the use of public funds. Despite this, in the last few years, debates on the inclusion of CBAs in the German health care system have paid little attention to the findings and practical experiences of scientific research. CBAs - especially the QALY - were instead represented a priori as "unfair" and "discriminatory." Today they have virtually no meaning when it comes to allocation and pricing decisions about publicly funded health services. Of course, CBAs are based on value judgments, which have to be communicated. They can lead to allocations that violate the minimum standards of justice. Here, distributive requirements and criteria are needed and must be developed in an interdisciplinary discourse. However, a general waiver of CBA does not make decisions about the allocation of resources easier, especially since its involvement can contribute to more openness and transparency in the system. Accordingly, for Germany a dual approach is recommended: an interdisciplinary exploration of the methodological foundations of economic evaluation and a consistent application of these in healthcare decisionmaking.
Schlagwörter
- Cost-benefit analysis, Decision support, Germany, Health economic evaluation, Value judgment
ASJC Scopus Sachgebiete
- Medizin (insg.)
- Öffentliche Gesundheit, Umwelt- und Arbeitsmedizin
Ziele für nachhaltige Entwicklung
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
in: Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, Jahrgang 55, Nr. 5, 05.2012, S. 660-667.
Publikation: Beitrag in Fachzeitschrift › Artikel › Forschung › Peer-Review
}
TY - JOUR
T1 - Entscheidungsunterstützung durch gesundheitsökonomische Evaluation in Deutschland aus Perspektive der Wissenschaft
AU - Von Der Schulenburg, J. M.Graf
PY - 2012/5
Y1 - 2012/5
N2 - For decades, economic evaluation studies, or cost-benefit analyses (CBA), have been a tool for decision support in the use of public funds. Despite this, in the last few years, debates on the inclusion of CBAs in the German health care system have paid little attention to the findings and practical experiences of scientific research. CBAs - especially the QALY - were instead represented a priori as "unfair" and "discriminatory." Today they have virtually no meaning when it comes to allocation and pricing decisions about publicly funded health services. Of course, CBAs are based on value judgments, which have to be communicated. They can lead to allocations that violate the minimum standards of justice. Here, distributive requirements and criteria are needed and must be developed in an interdisciplinary discourse. However, a general waiver of CBA does not make decisions about the allocation of resources easier, especially since its involvement can contribute to more openness and transparency in the system. Accordingly, for Germany a dual approach is recommended: an interdisciplinary exploration of the methodological foundations of economic evaluation and a consistent application of these in healthcare decisionmaking.
AB - For decades, economic evaluation studies, or cost-benefit analyses (CBA), have been a tool for decision support in the use of public funds. Despite this, in the last few years, debates on the inclusion of CBAs in the German health care system have paid little attention to the findings and practical experiences of scientific research. CBAs - especially the QALY - were instead represented a priori as "unfair" and "discriminatory." Today they have virtually no meaning when it comes to allocation and pricing decisions about publicly funded health services. Of course, CBAs are based on value judgments, which have to be communicated. They can lead to allocations that violate the minimum standards of justice. Here, distributive requirements and criteria are needed and must be developed in an interdisciplinary discourse. However, a general waiver of CBA does not make decisions about the allocation of resources easier, especially since its involvement can contribute to more openness and transparency in the system. Accordingly, for Germany a dual approach is recommended: an interdisciplinary exploration of the methodological foundations of economic evaluation and a consistent application of these in healthcare decisionmaking.
KW - Cost-benefit analysis
KW - Decision support
KW - Germany
KW - Health economic evaluation
KW - Value judgment
UR - http://www.scopus.com/inward/record.url?scp=84863903970&partnerID=8YFLogxK
U2 - 10.1007/s00103-012-1466-7
DO - 10.1007/s00103-012-1466-7
M3 - Artikel
C2 - 22526854
AN - SCOPUS:84863903970
VL - 55
SP - 660
EP - 667
JO - Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
JF - Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz
SN - 1436-9990
IS - 5
ER -